US Exchange Filings

Q/C Technologies Amends Preferred Stock Terms, Extends Series H Maturity

Q/C Technologies has pushed the maturity date on its Series H preferred stock back six months, while revising ownership limits and amendment rules for securities held by PharmaCyte Biotech. The changes reshape key investor terms, though the new limits were not disclosed.

Q/C Technologies amended terms governing its Series G and Series H preferred stock and certain warrants held by PharmaCyte Biotech, a holder of at least a majority of each preferred series. The changes cover amendment procedures and beneficial-ownership limits. Separately, the company finalized a previously agreed six-month extension to the Series H preferred stock’s maturity date.

  • Series G and Series H terms: Amendments to both preferred-stock designations revised provisions governing how their terms may be amended and changed the beneficial-ownership limits applicable to PharmaCyte. The company also amended the amendment and beneficial-ownership-limit provisions in PharmaCyte’s Series G long-term warrants.
  • Series H maturity extended: The maturity date moved from March 2, 2027, to September 2, 2027. PharmaCyte had consented to this change on November 15; the amendment took effect when the company filed it on November 20.
  • PharmaCyte’s role: Because PharmaCyte holds at least a majority of the outstanding shares of both preferred series, it qualifies as the required holder for amendments to those terms.
  • What is not specified: The announcement does not state the revised ownership-limit percentages or describe the detailed changes to amendment procedures. It does not identify a new financing or a change to the Series G preferred stock’s maturity.

The maturity extension gives the Series H preferred stock an additional six months before it comes due. The ownership-limit changes affect the terms applicable to PharmaCyte, but their precise effect cannot be determined without the amended provisions.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.